Reply to “What Types of Candida Infections Should Be Included When Evaluating Breakthrough Infections during Posaconazole Prophylaxis?”

Eitemau Tebyg

• What Types of Candida Infections Should Be Included When Evaluating Breakthrough Infections during Posaconazole Prophylaxis?
  gan: Blennow, Ola, et al.
  Cyhoeddwyd: (2013)
• Reply—Letter to the Editor: What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion
  gan: Vellucci, R., et al.
  Cyhoeddwyd: (2016)
• Fatal Breakthrough Mucormycosis in an Acute Myelogenous Leukemia Patient while on Posaconazole Prophylaxis
  gan: Kang, Seung Hun, et al.
  Cyhoeddwyd: (2015)
• When should surgery be considered for the treatment of epilepsy?
  gan: Burneo, Jorge G., et al.
  Cyhoeddwyd: (2005)
• Posaconazole Exposure-Response Relationship: Evaluating the Utility of Therapeutic Drug Monitoring
  gan: Dolton, Michael J., et al.
  Cyhoeddwyd: (2012)